Aqualung Therapeutics Corp.

Quick facts

Phase 2 pipeline

• ALT-100 · Immunology
  ALT-100 is an investigational immunotherapy designed to modulate immune responses, likely through targeting specific immune checkpoints or enhancing T-cell activation.
• ALT-100 mAb
  ALT-100 mAb is a monoclonal antibody that targets an unspecified molecular target.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aqualung Therapeutics Corp. portfolio CI brief
• Aqualung Therapeutics Corp. pipeline updates RSS